Business Context and Reporting Period
This Form 8-K was filed by Integrity Applications, Inc. (not Glucotrack, Inc.) on June 23, 2017, reporting events occurring on June 22, 2017. The company, incorporated in Delaware with principal offices in Ashdod, Israel, entered into a Securities Purchase Agreement with accredited investors. This transaction represents the eleventh closing of an ongoing offering of Units.
Key Financial Metrics and Transaction Details
- Gross Proceeds: $660,000 received from the sale of 660 Units.
- Unit Composition: Each Unit consists of one share of Series C 5.5% Convertible Preferred Stock, a Series C-1 Warrant (exercise price $4.50), and a Series C-2 Warrant (exercise price $7.75).
- Conversion and Exercise Potential: The Preferred Stock is convertible into 146,675 shares of Common Stock. The Warrants are exercisable for an aggregate of 293,350 shares of Common Stock.
- Placement Agent Compensation: The company paid a 10% commission (cash and stock) plus a 3% expense allowance. Additionally, the agent received warrants to purchase 29,334 shares at $4.50 and 14,667 shares at $7.75.
Note: This filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics for the company's operations.
Material Changes and Prior Activity
This filing details the eleventh closing of a capital raise. The terms of the Preferred Stock and Warrants are identical to those issued in ten prior closings disclosed in previous 8-K filings between April 2016 and May 2017. The prior issuances involved an aggregate of 10,343.9 Units. There are no material changes to the terms of the offering compared to previous closings.
Guidance, Risks, and Unusual Items
- Unregistered Sales: The Units were sold without registration under the Securities Act of 1933, relying on the Section 4(a)(2) exemption for accredited investors.
- Registration Rights: A Registration Rights Agreement was executed, substantially identical to agreements with prior purchasers.
- Anti-Dilution: Warrants issued to the Placement Agent include full ratchet anti-dilution protection and cashless exercise options, which differ from the standard Warrants issued to investors.
- Outlook: The filing contains no forward-looking guidance, management commentary on operations, or discussion of risks beyond the standard disclosure of unregistered securities sales.
Investor Verification Checklist
- Verify the total capital raised across all eleven closings to assess the company's current cash runway.
- Confirm the total number of outstanding shares of Common Stock to calculate the potential dilution from the 146,675 convertible shares and 293,350 warrant shares.
- Review the "Prior 8-Ks" referenced in the filing to understand the full scope of the Series C Preferred Stock outstanding.
- Assess the impact of the Placement Agent's full ratchet anti-dilution protection on future equity valuations.